AR114419A1 - Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígado - Google Patents
Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígadoInfo
- Publication number
- AR114419A1 AR114419A1 ARP190100505A ARP190100505A AR114419A1 AR 114419 A1 AR114419 A1 AR 114419A1 AR P190100505 A ARP190100505 A AR P190100505A AR P190100505 A ARP190100505 A AR P190100505A AR 114419 A1 AR114419 A1 AR 114419A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- benzyl
- amino
- propylsulfonimidoyl
- carbonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018077501 | 2018-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114419A1 true AR114419A1 (es) | 2020-09-02 |
Family
ID=65685310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100505A AR114419A1 (es) | 2018-02-28 | 2019-02-28 | Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígado |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3758707A1 (zh) |
| JP (1) | JP7089596B2 (zh) |
| KR (1) | KR20200128414A (zh) |
| CN (1) | CN111801100B (zh) |
| AR (1) | AR114419A1 (zh) |
| AU (1) | AU2019228654A1 (zh) |
| BR (1) | BR112020016509A2 (zh) |
| CA (1) | CA3091950A1 (zh) |
| CL (1) | CL2020002139A1 (zh) |
| CO (1) | CO2020010306A2 (zh) |
| IL (1) | IL276817A (zh) |
| MA (1) | MA52412A (zh) |
| MX (1) | MX2020008746A (zh) |
| PE (1) | PE20211456A1 (zh) |
| PH (1) | PH12020551343A1 (zh) |
| RU (1) | RU2020131012A (zh) |
| SG (1) | SG11202008291XA (zh) |
| TW (1) | TW202003518A (zh) |
| WO (1) | WO2019166432A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP7065989B2 (ja) | 2018-02-28 | 2022-05-12 | ノバルティス アーゲー | インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０－（ジ（フェニル）メチル）－４－ヒドロキシ－８，９，９ａ，１０－テトラヒドロ－７Ｈ－ピロロ［１’，２’：４，５］ピラジノ［１，２－ｂ］ピリダジン－３，５－ジオン誘導体および関連化合物 |
| KR102409595B1 (ko) | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 |
| CN112420196A (zh) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | 急性心肌梗死患者5年内生存率的预测方法和系统 |
| WO2024013205A1 (en) * | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Phosphorylpurinone compounds for the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| TW201639852A (zh) | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| CA2760766A1 (en) * | 2009-05-21 | 2010-11-25 | Nicholas James Bennett | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
| US8962652B2 (en) * | 2009-10-22 | 2015-02-24 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| US20120039916A1 (en) * | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| SI3294740T1 (sl) * | 2015-05-08 | 2019-12-31 | F. Hoffmann-La Roche Ag | Nove sulfonimidoilpurinonske spojine in derivati za zdravljenje virusne okužbe in zaščito pred njo |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| WO2018041763A1 (en) | 2016-08-29 | 2018-03-08 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| JP7101663B2 (ja) * | 2016-09-13 | 2022-07-15 | エフ．ホフマン－ラ ロシュ アーゲー | Ｔｌｒ７アゴニストとｈｂｖキャプシドアセンブリ阻害剤の併用療法 |
-
2019
- 2019-02-26 EP EP19708981.6A patent/EP3758707A1/en active Pending
- 2019-02-26 CA CA3091950A patent/CA3091950A1/en active Pending
- 2019-02-26 WO PCT/EP2019/054729 patent/WO2019166432A1/en active Application Filing
- 2019-02-26 MX MX2020008746A patent/MX2020008746A/es unknown
- 2019-02-26 MA MA052412A patent/MA52412A/fr unknown
- 2019-02-26 BR BR112020016509-3A patent/BR112020016509A2/pt not_active Application Discontinuation
- 2019-02-26 SG SG11202008291XA patent/SG11202008291XA/en unknown
- 2019-02-26 RU RU2020131012A patent/RU2020131012A/ru unknown
- 2019-02-26 CN CN201980015912.7A patent/CN111801100B/zh active Active
- 2019-02-26 PE PE2020001228A patent/PE20211456A1/es unknown
- 2019-02-26 JP JP2020544794A patent/JP7089596B2/ja active Active
- 2019-02-26 KR KR1020207027935A patent/KR20200128414A/ko unknown
- 2019-02-26 AU AU2019228654A patent/AU2019228654A1/en not_active Abandoned
- 2019-02-27 TW TW108106752A patent/TW202003518A/zh unknown
- 2019-02-28 AR ARP190100505A patent/AR114419A1/es unknown
-
2020
- 2020-08-19 CL CL2020002139A patent/CL2020002139A1/es unknown
- 2020-08-19 IL IL276817A patent/IL276817A/en unknown
- 2020-08-21 CO CONC2020/0010306A patent/CO2020010306A2/es unknown
- 2020-08-27 PH PH12020551343A patent/PH12020551343A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL276817A (en) | 2020-10-29 |
| MA52412A (fr) | 2021-06-02 |
| BR112020016509A2 (pt) | 2020-12-15 |
| CO2020010306A2 (es) | 2020-08-31 |
| PH12020551343A1 (en) | 2021-06-21 |
| PE20211456A1 (es) | 2021-08-05 |
| EP3758707A1 (en) | 2021-01-06 |
| KR20200128414A (ko) | 2020-11-12 |
| WO2019166432A1 (en) | 2019-09-06 |
| CN111801100A (zh) | 2020-10-20 |
| JP7089596B2 (ja) | 2022-06-22 |
| AU2019228654A1 (en) | 2020-09-03 |
| MX2020008746A (es) | 2020-09-28 |
| RU2020131012A (ru) | 2022-03-28 |
| SG11202008291XA (en) | 2020-09-29 |
| CN111801100B (zh) | 2023-10-24 |
| CA3091950A1 (en) | 2019-09-06 |
| TW202003518A (zh) | 2020-01-16 |
| JP2021514972A (ja) | 2021-06-17 |
| CL2020002139A1 (es) | 2021-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114419A1 (es) | Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígado | |
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR088748A1 (es) | Macrociclos como inhibidores del factor xia | |
| CL2021002104A1 (es) | Compuestos, composiciones y métodos. | |
| CL2017002207A1 (es) | Inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| PH12016501066A1 (en) | ROR GAMMA (ROYy) MODULATORS | |
| AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
| AR091490A1 (es) | Antagonistas de iap | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| AR117206A1 (es) | Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer | |
| AR118768A1 (es) | Derivados de pirimidina como inhibidores de las cinasas jak | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CO2022004391A2 (es) | Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4 | |
| AR121878A1 (es) | DERIVADOS DE BENZODIAZEPINA COMO PAM DE GABAA g1 | |
| AR097794A1 (es) | Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b | |
| AR120170A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |